Pfizer (NYSE:PFE) is looking to expand the use of the antiviral Paxlovid, which FDA has authorized to treat mild-to-moderate COVID-19 in individuals who are at least 12 years of age who weigh at least 40 kg. The authorization covers individuals with a risk of developing severe disease. A recently launched Phase 2/3 study will test…